Cargando…

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL‐2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Huemer, Florian, Melchardt, Thomas, Jansko, Bettina, Wahida, Adam, Jilg, Stefanie, Jost, Philipp J., Klieser, Eckhard, Steiger, Katja, Magnes, Teresa, Pleyer, Lisa, Greil‐Ressler, Sigrun, Rass, Christof, Greil, Richard, Egle, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849823/
https://www.ncbi.nlm.nih.gov/pubmed/30725494
http://dx.doi.org/10.1111/ejh.13218